公开(公告)号：US12195424B2

公开(公告)日：2025-01-14

申请号：US17456244

申请日：2021-11-23

Applicant: The General Hospital Corporation ,  Temple University—Of The Commonwealth System of Higher Education ,  Rhode Island Hospital, A Lifespan-Partner

Inventor： Frederick M. Ausubel ,  Wooseong Kim ,  Eleftherios Mylonakis ,  William M. Wuest

IPC: A61P31/00 ,  A61K31/192 ,  A61P31/04 ,  A61P31/06 ,  A61P31/08 ,  C07C39/17 ,  C07C65/11 ,  C07C65/17 ,  C07C235/66 ,  A01N31/08 ,  A61K31/05 ,  A61K45/06

Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.

公开(公告)号：US10723799B2

公开(公告)日：2020-07-28

申请号：US16100065

申请日：2018-08-09

Applicant: I-MAB

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61K39/395 ,  A61P31/20 ,  A61P31/14 ,  A61P35/00 ,  A61P35/02 ,  A61P31/18 ,  A61P31/22 ,  A61P31/08 ,  A61P31/04 ,  A61P31/06 ,  A61P31/16 ,  A61K35/17 ,  A61K39/00

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US20180311232A1

公开(公告)日：2018-11-01

申请号：US15770674

申请日：2016-10-20

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin HU

IPC: A61K31/4745 ,  A61K9/00 ,  A61P31/06 ,  A61P31/08

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0073 ,  A61K31/351 ,  A61K31/7036 ,  A61K2300/00 ,  A61P31/06 ,  A61P31/08 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/475 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483

Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20120171204A1

公开(公告)日：2012-07-05

申请号：US13166982

申请日：2011-06-23

Applicant: Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

Inventor： Douglas Adam Levinson ,  Clare M. Lloyd ,  Sean A. McCarthy

IPC: A61K39/395 ,  A61P11/06 ,  A61P37/08 ,  A61P27/02 ,  G01N33/53 ,  A61P31/08 ,  C07K19/00 ,  C12Q1/68 ,  G01N21/64 ,  A61P37/00 ,  A61P33/02

CPC classification number: C07K14/47

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders, and also for the treatment of mast cell-related processes and disorders, ischemic disorders and injuries, including ischemic renal disorders and injuries. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials. Methods are also provided for the treatment of symptoms associated with mast cell-related processes or disorders and ischemic disorders and injuries using the genes, gene products and antibodies of the invention.

Abstract translation: 本发明涉及用于治疗和诊断免疫疾病，特别是T辅助淋巴细胞相关病症的方法和组合物，还涉及治疗肥大细胞相关过程和病症，缺血性疾病和损伤，包括缺血性肾病和损伤 。 例如，识别在T辅助细胞（TH）细胞和TH细胞亚群内部和之间差异表达的基因，其包括但不限于TH0，TH1和TH2细胞亚群。 基因也通过其基因产物与涉及TH细胞和TH细胞亚群的分化，维持和效应子功能的基因产物相互作用的能力进行鉴定。 所鉴定的基因可以诊断使用或作为治疗干预的靶标。 在这方面，本发明提供了用于鉴定和治疗性使用化合物作为免疫疾病，特别是TH细胞亚群相关病症治疗的方法。 另外，提供了用于TH细胞亚群相关病症的诊断评估和预后的方法，用于鉴定表现出对这些病症倾向的受试者，用于监测接受临床评估治疗这种病症的患者，以及用于监测 化合物用于临床试验。 还提供了使用本发明的基因，基因产物和抗体治疗与肥大细胞相关过程或病症相关的症状以及缺血性疾病和损伤的方法。

公开(公告)号：US20120095055A1

公开(公告)日：2012-04-19

申请号：US13375551

申请日：2010-05-24

Applicant: Helen J. Mitchell ,  Danielle M. Hurzy ,  Mildred K. Kaufman

Inventor： Helen J. Mitchell ,  Danielle M. Hurzy ,  Mildred K. Kaufman

IPC: A61K31/4439 ,  C07D231/54 ,  A61K31/416 ,  A61P37/06 ,  A61P35/02 ,  A61P5/00 ,  A61P35/00 ,  A61P7/00 ,  A61P25/00 ,  A61P3/10 ,  A61P7/02 ,  A61P3/04 ,  A61P3/00 ,  A61P1/00 ,  A61P19/04 ,  A61P29/00 ,  A61P27/02 ,  A61P37/08 ,  A61P11/00 ,  A61P11/06 ,  A61P1/04 ,  A61P31/14 ,  A61P1/16 ,  A61P17/14 ,  A61P17/06 ,  A61P31/08 ,  A61P31/22 ,  A61P17/10 ,  A61P31/18 ,  A61P25/28 ,  A61P25/24 ,  A61P25/30 ,  A61P25/18 ,  A61P25/22 ,  A61P17/00 ,  C07D401/08

CPC classification number: A61K31/416 ,  C07D231/54 ,  C07D401/04 ,  C07D401/06

Abstract: The present invention encompasses compounds of Formula (I): or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.

Abstract translation: 本发明包括式（I）化合物或其药学上可接受的盐或水合物，其可用作治疗各种自身免疫性和炎性疾病或病症的选择性糖皮质激素受体配体。 还包括药物组合物和使用方法。

公开(公告)号：US20110306644A1

公开(公告)日：2011-12-15

申请号：US13093530

申请日：2011-04-25

Applicant: William J. Hoekstra ,  Robert J. Schotzinger ,  Stephen W. Rafferty

Inventor： William J. Hoekstra ,  Robert J. Schotzinger ,  Stephen W. Rafferty

IPC: A61K31/4439 ,  A61P33/02 ,  A61P31/10 ,  A61P33/06 ,  A61P31/04 ,  C07D401/06 ,  A61P31/08

CPC classification number: C07D401/06

Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Abstract translation: 本发明描述了具有金属酶调节活性的化合物，以及治疗由这些金属酶介导的疾病，病症或症状的方法。

公开(公告)号：US20110263684A1

公开(公告)日：2011-10-27

申请号：US13120601

申请日：2009-09-25

Applicant: Antonin de Fougerolles ,  Tatiana Novobrantseva ,  Gregory Hinkle

Inventor： Antonin de Fougerolles ,  Tatiana Novobrantseva ,  Gregory Hinkle

IPC: A61K31/713 ,  C12N5/071 ,  C12N15/63 ,  A61P29/00 ,  A61P1/00 ,  A61P11/00 ,  A61P35/00 ,  A61P35/02 ,  A61P19/02 ,  A61P31/08 ,  A61P43/00 ,  A61P17/10 ,  A61P1/16 ,  A61P31/00 ,  A61P13/12 ,  C07H21/02

CPC classification number: C12N15/113 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/344 ,  C12N2310/3515

Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.

Abstract translation: 本发明涉及靶向血清淀粉样蛋白A（SAA）基因的双链核糖核酸（dsRNA）以及使用dsRNA抑制SAA表达的方法。

公开(公告)号：US20110145941A1

公开(公告)日：2011-06-16

申请号：US12866184

申请日：2009-02-04

Applicant: Fabio Benigni ,  Daniele D'Ambrosio

Inventor： Fabio Benigni ,  Daniele D'Ambrosio

IPC: A01K67/027 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P29/00 ,  A61P25/28 ,  A61P3/10 ,  A61P31/08 ,  A61P31/18 ,  G01N33/53 ,  C07H21/04 ,  C12N15/63

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  Y02E50/10 ,  Y02E50/30

Abstract: An anti-TrkA antibody is provided that comprises:a) a variable heavy chain comprising a sequence selected from any of BXhVH1, BXhVH2, BXhVH3, BXhVH4, BXhVH5, or HuVHWOv as shown in FIG. 1a; or from variants of any of said sequences and/or b) a variable light chain comprising a sequence selected from any of BXhVL1, BXhVL2, BXhVL3, BXhVL4, BXhVL5, BXhVL6, BXhVL7 or BXhVL8; as shown in FIG. 1b, or from variants of any of said sequences. TrkA-binding derivatives are also provided. Antibodies or derivatives of the present invention are useful in a number of therapies, including pain therapy.

Abstract translation: 提供了抗TrkA抗体，其包含：a）包含选自BXhVH1，BXhVH2，BXhVH3，BXhVH4，BXhVH5或HuVHWOv中的任一种的序列的可变重链，如图1所示。 1a; 或者来自任何所述序列的变体和/或b）包含选自BXhVL1，BXhVL2，BXhVL3，BXhVL4，BXhVL5，BXhVL6，BXhVL7或BXhVL8中的任一个的序列的可变轻链; 如图1所示。 1b，或来自任何所述序列的变体。 还提供了TrkA结合衍生物。 本发明的抗体或衍生物可用于许多疗法，包括疼痛治疗。

公开(公告)号：US20110020325A1

公开(公告)日：2011-01-27

申请号：US12920021

申请日：2009-02-27

Applicant: Eugene D. Kwon ,  John C. Cheville ,  Thomas J. Sebo ,  Brant A. Inman

Inventor： Eugene D. Kwon ,  John C. Cheville ,  Thomas J. Sebo ,  Brant A. Inman

IPC: A61K39/395 ,  A61K31/713 ,  A61P31/06 ,  A61P31/08

CPC classification number: C07K16/2827 ,  C12N15/1138

Abstract: This document provides methods and materials for reducing bacterial induced granulomatous inflammation in a mammal using agents that reduce B7-H1 expression or activity.

Abstract translation: 本文提供了减少B7-H1表达或活性的药物减少哺乳动物细菌性肉芽肿炎症的方法和材料。

公开(公告)号：US20100152098A1

公开(公告)日：2010-06-17

申请号：US12613329

申请日：2009-11-05

Applicant: Tomasz Glinka ,  Olga Rodny ,  Keith A. Bostian ,  David M. Wallace ,  Robert I. Higuchi ,  Chun Chow ,  Chi Ching Mak ,  Gavin Hirst ,  Brian Eastman

Inventor： Tomasz Glinka ,  Olga Rodny ,  Keith A. Bostian ,  David M. Wallace ,  Robert I. Higuchi ,  Chun Chow ,  Chi Ching Mak ,  Gavin Hirst ,  Brian Eastman

IPC: A61K38/05 ,  A61K38/02 ,  C07D265/30 ,  C07D241/42 ,  C07D215/38 ,  C07D211/58 ,  C07D211/06 ,  C07D213/643 ,  C07D213/74 ,  C07D231/12 ,  C07D209/20 ,  C07D207/14 ,  C07D333/24 ,  C07D321/10 ,  C07D319/18 ,  C07D309/10 ,  C07D307/79 ,  C07C311/46 ,  C07C237/20 ,  A61P31/08 ,  A61P31/06 ,  A61P31/04 ,  C07D217/22 ,  A61K31/472

CPC classification number: C07K5/06086 ,  A61K38/00 ,  C07K5/06104 ,  C07K5/06113 ,  C07K5/06139 ,  C07K5/06191 ,  Y02A50/401 ,  Y02A50/47 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/483

Abstract: Disclosed are compounds having polybasic functionalities. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.

Abstract translation: 公开了具有多碱性官能团的化合物。 该化合物抑制细菌外排泵抑制剂，并与抗菌剂组合使用以治疗或预防细菌感染。 这些组合可以有效地抵抗通过外排泵机制对抗细菌剂产生抗性的细菌感染。